Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Wall St set for higher open on hopes of progress in stimulus talks

10/23/2020 | 08:35am EST

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)

* Gilead up as remdesivir wins approval for treating COVID in U.S.

* Intel slumps as quarterly margins fall

* American Express falls as profit falls short of estimates

* Futures up: Dow and S&P 0.3%, Nasdaq 0.2%

Oct 23 (Reuters) - Wall Street's main indexes were set for a higher open on Friday, with investors anticipating progress in bipartisan talks over the next coronavirus aid bill as the Nov. 3 presidential election gets closer.

White House Chief of Staff Mark Meadows late on Thursday said that negotiations with lawmakers on a coronavirus relief package, now totaling $1.9 trillion, have entered a new phase with congressional committee chairs meeting and the two sides trading technical language.

"The stimulus talks are continuing so the market is happy about that even though we probably won't get anything done before the election," said Thomas Hayes, managing member at Great Hill Capital LLC in New York.

U.S. House Speaker Nancy Pelosi said on Thursday there was progress in negotiations with the White House, but Senate Republicans remained skeptical of a possible deal costing trillions of dollars.

Uncertainly over the timeline of the relief legislature has been weighing on Wall Street's major indexes, which were set to end a choppy week slightly lower.

Meanwhile, a record 47 million Americans cast ballots, eclipsing total early voting from the 2016 election. President Donald Trump and Democratic rival Joe Biden debated on Thursday for the last time to persuade the few remaining undecided voters 12 days before their contest.

Heading into the debate, Trump trailed former vice president Biden in national polls, but the contest is much tighter in some battleground states where the election will likely be decided.

At 08:08 a.m. ET, Dow E-minis were up 0.31% at 28,355 points, S&P 500 E-minis rose 0.28% to 3,458.75 points and Nasdaq 100 E-minis gained 0.19% to 11,673.5 points.

Third-quarter earnings season chugged along with 126 S&P 500 firms having reported so far. About 84% of them have topped quarterly profit estimates, according to Refinitiv data.

Chipmaker Intel Corp tumbled nearly 10% in premarket trading after it reported that margins fell as consumers bought cheaper laptops and pandemic-stricken businesses and governments clamped down on data center spending.

Gilead Sciences Inc jumped 4% as its antiviral drug remdesivir became the first and only drug approved for treating patients hospitalized with COVID-19 in the United States.

American Express Co dropped 2.8% as it missed third-quarter profit estimates after its customers spent less during the COVID-19 fueled economic slowdown and it set aside money for potential payment defaults. (Reporting by Medha Singh and Shivani Kumaresan in Bengaluru; Editing by Arun Koyyur, Bernard Orr)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
AMERICAN EXPRESS COMPANY 2.00% 122.33 Delayed Quote.-3.66%
DJ INDUSTRIAL 0.20% 29883.79 Delayed Quote.3.86%
GILEAD SCIENCES, INC. 0.02% 61.13 Delayed Quote.-5.94%
INTEL CORPORATION 0.69% 49.9 Delayed Quote.-19.21%
NASDAQ 100 0.01% 12456.406964 Delayed Quote.42.62%
NASDAQ COMP. -0.05% 12349.366333 Delayed Quote.35.96%
S&P 500 0.18% 3669.01 Delayed Quote.13.36%
All news about GILEAD SCIENCES, INC.
05:27pGILEAD SCIENCES : Medical journal editorial refutes WHO finding on Gilead's remd..
12/01GILEAD SCIENCES : Canada Announces Notice of Compliance for DESCOVY® (emtricitab..
11/25EU seeks to bypass patents to boost drugs access in crises
11/24GILEAD SCIENCES : to Present at the 3rd Annual Evercore ISI HealthCONx Conferenc..
11/23GILEAD SCIENCES : to Present at the 3rd Annual Evercore ISI HealthCONx Conferenc..
11/23Canada could approve COVID-19 vaccines early next year -regulator
11/23GILEAD SCIENCES : U.S. infectious disease group backs Gilead's remdesivir for CO..
11/21FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug -- Update
11/20WALL STREET STOCK EXCHANGE : Stocks decline as COVID-19 cases surge
11/20NEWS HIGHLIGHTS : Top Company News of the Day
More news
Financials (USD)
Sales 2020 23 650 M - -
Net income 2020 34,3 M - -
Net Debt 2020 20 525 M - -
P/E ratio 2020 -4 484x
Yield 2020 4,46%
Capitalization 76 616 M 76 616 M -
EV / Sales 2020 4,11x
EV / Sales 2021 3,92x
Nbr of Employees 11 800
Free-Float 99,6%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 73,52 $
Last Close Price 61,12 $
Spread / Highest target 71,8%
Spread / Average Target 20,3%
Spread / Lowest Target -5,10%
EPS Revisions
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.64.21%39 976
BIONTECH SE236.51%27 452
GENMAB A/S58.76%24 885